Core Viewpoint - Xianle Health Technology Co., Ltd. held an investor relations event to discuss the strategic implementation and operational performance for the first half of 2025, engaging with 59 institutional investors [1][2]. Group 1: Operational Performance - In the first half of 2025, the company achieved a revenue of 2.042 billion, representing a year-on-year growth of 2.57% [3][4]. - The net profit attributable to shareholders was 161 million, reflecting a year-on-year increase of 4.30% [3][4]. - The China region reported a revenue of 818 million, a decline of 1.63%, while new consumer orders showed significant growth [3]. - The Americas generated 760 million in revenue, up 4.26%, and Europe saw a revenue increase of 21.96% to 359 million [3]. Group 2: Business Segments - The core strategic soft capsule segment grew by 6.5%, benefiting from internal business and BF collaboration [4]. - The gummy business also saw a revenue increase of 6.4%, driven by global demand and large export orders [4]. - Tablet sales surged by 33.4%, capitalizing on growth opportunities, while hard capsules grew by 11% [4]. Group 3: Cash Flow and Financial Management - The company reported a 39.7% year-on-year increase in net cash inflow from operating activities, indicating strong cash flow management [4].
调研速递|仙乐健康接受金鼎资本等59家机构调研,上半年营收20.42亿元亮点多